Sisvel Grants a Patent License to Samsung under the Hera Wi-Fi Patents
7.6.2018 18:59:00 EEST | Business Wire | Press release
Hera Wireless S.A. (“Hera“) and Samsung Electronics Co. Ltd. (“Samsung“) today announced that they have entered into a Wi-Fi patent license agreement, brokered by Sisvel UK Limited (“Sisvel“). Samsung thereby joins the growing list of companies around the world that have access to the portfolio of patents held by Hera, which are essential to the IEEE Wi-Fi Standard.
The agreement between Samsung and Hera settles a dispute related to Hera’s patents and it provides for a multi-year worldwide patent license covering the sale and distribution of certain Wi-Fi enabled Samsung products.
The Hera portfolio originated with Sanyo Electric of Japan. Sanyo was deeply involved in the development of this technology standard and was a forerunner of Wi-Fi technological innovation. The Hera portfolio is comprised of over 100 patents, including international coverage with filings in over 40 countries.
“We are pleased to conclude an agreement with Samsung that reflects the strength of Hera’s patent portfolio, and we are very happy to welcome them to our ever-growing family of licensees,” said Nick Webb, Managing Director of Sisvel UK Limited.
About Hera & Sisvel: Hera is a wholly owned subsidiary of Sisvel International S.A., the holding company of the Sisvel Group. Sisvel is a world leader in managing intellectual property and maximizing the value of patent rights. Founded in 1982, the Sisvel Group is global in scope and reach, with companies in Italy, the United States, China, Japan, Germany, Luxembourg, and the United Kingdom, with over one hundred professionals worldwide with technical, legal, and licensing expertise. Sisvel has a long history of managing successful patent portfolios including those related to the audio compression standards known as MP3 and MPEG Audio.
Sisvel currently operates patent pools and joint licensing programs for the DVB-T2, MCP, LTE/LTE-A, 3G, Wi-Fi and Recommendation Engine, together with its Sisvel Wireless licensing program.
For additional information, please visit: www.sisvel.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180607005900/en/
Contact information
Sisvel Group
Giulia Dini, +44 203 053 6930
Communications
Manager
giulia.dini@sisvel.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AV Access Presents eShare W90: A 4K Wireless Conferencing System for Smarter Hybrid Meetings at ISE 2026 in Barcelona28.1.2026 10:00:00 EET | Press release
AV Access proudly announces its participation in ISE 2026, one of the world’s leading AV and systems integration exhibitions. From February 3-6 at the Fira de Barcelona, Gran Via, the company will showcase its latest solutions designed to improve collaboration, enhance entertainment, and boost workplace productivity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260128178621/en/ The eShare W90 wireless presentation and conferencing system makes hybrid meetings more secure, more collaborative, and far easier to manage. At Booth 1F110, AV Access will highlight its flagship innovations, including the eShare W90 wireless conferencing system, the plug-and-play 4KIP200 HDMI over IP solution, and the complete iDock series of KVM docking stations—demonstrating its dedication to versatile, high-performance AV technology. Stream, Charge and Share with a Single USB-C Cable At the heart of the booth is the eShare W90 wireless presentat
SES Extends EGNOS GEO-1 Satellite Service to Power Precise Navigation Across Europe28.1.2026 09:50:00 EET | Press release
SES, a leading space solutions company, and the European Union Agency for the Space Programme (EUSPA) today announced an extension of the European Geostationary Navigation Overlay Service (EGNOS) GEO-1 satellite service agreement through 2030, with an option to extend until 2032, helping maintain high-precision navigation services for aviation and other critical users across Europe. By improving the accuracy and integrity of satellite positioning signals, EGNOS supports aircraft in landing in low-visibility conditions, as well as planning more efficient routes, reducing fuel burn and CO₂ emissions. At the core of the EGNOS service is Europe’s regional Satellite-Based Augmentation System (SBAS) that improves the accuracy and reliability of Global Navigation Satellite System (GNSS) signals, such as GPS. Beyond aviation, EGNOS supports maritime navigation and precision-driven agriculture, contributing to efficient operations and sustainability by reducing fuel consumption and emissions. U
LTTS Secures Strategic Engineering and R&D Agreement from Global Automotive OEM28.1.2026 09:30:00 EET | Press release
L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, announced that it has secured a significant multi-year engagement in its Mobility segment from a leading automotive OEM. The strategic win further strengthens LTTS’ long-standing partnership with the premium automotive manufacturer and underscores its growing role in supporting next-generation mobility engineering. The engagement encompasses advanced software, connectivity and digital engineering services across multiple vehicle technology domains. LTTS will draw on its global engineering expertise, strong domain knowledge and proven delivery frameworks to support the customer’s evolving product and technology roadmap. This win reinforces LTTS’ comprehensive mobility engineering capabilities, spanning embedded systems, digital platforms, verification and validation, cloud integration, cybersecurity, and cross-disciplinary software–mechanical engineering. LTTS’ investments in sta
SFI Health™ EMEA Announces the Launch in Poland of Equazen ® Forte, Marking a New Chapter in Cognitive Support for Young Adults and Adults28.1.2026 09:00:00 EET | Press release
SFI Health™ EMEA, the regional entity of SFI Health™, a global leader in natural healthcare, today is pleased to announce the launch of Equazen® Forte in Poland, a new concentrated omega 3 product formulation to be added to the Equazen® range designed to support the normal cognitive performance for young adults and adults. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260127646023/en/ Equazen® Forte: a key milestone in the brand’s long-term development strategy. Equazen® Forte represents a key milestone in the brand’s long-term development strategy. Traditionally recognized as a pediatric brain health expert, Equazen® is now evolving to support consumers across different life stages, addressing changing cognitive demands from adolescence into adulthood. Equazen® Forte builds on more than 25 years of Equazen® heritage and scientific expertise. Like the rest of the Equazen® range, it features the brand’s unique and clinically
Fujirebio Expands Its Neuro Testing Portfolio With the Launch of the Fully Automated Lumipulse® G pTau 217 CSF Assay for Research Use Only28.1.2026 08:07:00 EET | Press release
H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G pTau 217 CSF assay for the fully automated LUMIPULSE® G immunoassay analyzers. This CLEIA (chemiluminescent enzyme immunoassay) assay is available for Research Use Only (RUO) and allows for the quantitative measurement of Tau phosphorylated at threonine 217 (pTau 217) in human cerebrospinal fluid (CSF) within just 35 minutes. Alzheimer’s disease (AD) is characterized by the accumulation of neurofibrillary tangles in the brain, composed of hyperphosphorylated tau, and amyloid plaques, consisting of distinct β-amyloid peptides. CSF pTau217 has emerged as an early biomarker for neuropathological changes associated with AD. This new immunoassay further strengthens Fujirebio’s growing portfolio of neurological biomarkers and reinforces the company’s leading position in the advancement of associated research tools and diagnostics. “By adding pTau 217 CSF to our neuro portfol
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom